Clinical Trial: Therapeutic Effect of Upatidacinib in Primary Sjogren's Syndrome

U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06862284) titled 'Therapeutic Effect of Upatidacinib in Primary Sjogren's Syndrome' on March 01.

Brief Summary: This study is designed to explore the efficacy and safety of upadacitinib and clarify the influence on immune function in the treatment of primary Sjogren's Syndrome.

Study Start Date: March 10

Study Type: INTERVENTIONAL

Condition: Primary Sjogren's Syndrome (pSS)

Intervention: DRUG: Upadacitinib (ABT-494)

Upadacitinib 15mg Qd for 52 weeks

DRUG: Hydroxychloroquine (HCQ)

Hydroxychloroquine 200mg Bid for 52 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Peking University People's Hospital

Information provided by (Responsibl...